Skip to main content
SpringerLink
Log in

BioAlliance Pharma has suspended the doxorubicin Transdrug® phase II/III trial

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. BioAlliance Pharma SA.BioAlliance Pharma Suspends the Phase II/III Trial of Doxorubicin Transdrug (Rm) In Primary Liver Cancer, Following Advice from the Drug Safety Monitoring Board and the Steering Committee. Media Release: 16 Jul 2008. Available from: URL: http://www.bioalliancepharma.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

BioAlliance Pharma has suspended the doxorubicin Transdrug® phase II/III trial. React. Wkly. 1212, 2 (2008). https://doi.org/10.2165/00128415-200812120-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200812120-00005

Keywords

Search

Navigation